Acrivon reports Q4 2023 net loss of $19.3M; cash runway into Q4 2025

Acrivon Therapeutics, Inc.

Net loss Q4 2023 $19.3M, full year $60.4M; R&D expenses $15.5M/$46.0M.
Cash, equivalents and marketable securities $127.5M at Dec 31, 2023; funds operations into Q4 2025.
ACR-368 Phase 2 trial enrolling; Phase 1b combo with gemcitabine completed; ACR-2316 IND studies advancing.
Two abstracts accepted for AACR 2024 on ACR-2316 and ACR-368 resistance mechanism.
Appointed Jean-Marie Cuillerot as CMO; added two new board members.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Acrivon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income $19.3 million and $60.4 million, respectively.

Period: fourth quarter and full year ended December 31, 2023
Net income: $19.3 million and $60.4 million, respectively
Result: reported results

Exact text from the filing

Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-037627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.